NCT04634552 2026-03-17MonumenTAL-1Janssen Research & Development, LLCPhase 2 Recruiting510 enrolled 1 FDA
NCT02981628 2026-02-23Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaChildren's Oncology GroupPhase 2 Recruiting80 enrolled 1 FDA
NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT02074839 2025-06-08Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationServierPhase 1 Recruiting291 enrolled 3 FDA